Avalo Therapeutics 2025 Financial Review – Alphastreet

Company Overview

Avalo Therapeutics is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company’s lead asset, abdakibart, is currently advancing through a Phase 2 clinical trial for hidradenitis suppurativa.

Key Financial Figures

For the year ended December 31, 2025, Avalo reported total net revenues of $59 (in thousands). Additionally, the company recorded a basic and diluted net loss per share of $5.84.

Also Read

CrowdStrike takes on AI-enabled adversaries with new security offerings

Down 15% and a yield of 7.9%! Is this REIT dividend champion now irresistible?

Moody’s cuts rating on private credit fund run by KKR and Future Standard to junk as bad loans grow

Plugin developed by ProSEOBlogger. Get free gpl themes.

Additional Financial Insights

Avalo reported a total net loss of $78.3 million for the 2025 fiscal year. This was heavily driven by $50.1 million in research and development expenses to support their clinical trials. Moving forward, the company holds $98.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025, which is expected to successfully fund operations into 2028.